VENUSREM

Sat, 30 May, 2026

• News

  March 2026 standalone net sales results filed

  moneycontrol.com ↗

Thu, 28 May, 2026

• News

  Monthly sales results for March 2026 showing 33.48% Y-o-Y growth

  moneycontrol.com ↗
• News

  March 2026 consolidated net sales results filed

  moneycontrol.com ↗

Wed, 27 May, 2026

• News

  Q4 FY2026 consolidated net profit results filed

  business-standard.com ↗
• News

  Q4 FY2026 standalone net profit reported with 193.78% YoY growth

  business-standard.com ↗
• News

  Saudi FDA approval for Plerixafor is a regulatory milestone but

  business-standard.com ↗

Tue, 26 May, 2026

• Filing

  Dividend declaration announced

  NSE ↗
• Filing

  Leadership appointment as Whole Time Director effective May 26, 2026

  NSE ↗
• Filing

  Appointment of independent director effective May 26, 2026

  NSE ↗
• Filing

  Routine appointment disclosure of Manu Chaudhary as Whole Time Director effective October 1, 2026

  NSE ↗
• Filing

  Routine independent director appointment effective in future

  NSE ↗
• Filing

  Record date notification for dividend

  NSE ↗
• Filing

  Board recommended final dividend of Rs. 10 per share

  NSE ↗
• Filing

  Full-year financial results (FY2025-26) filed today by board approval

  NSE ↗
• Filing

  Routine dividend announcement under Regulation 30 LODR

  BSE ↗
• Filing

  Board meeting scheduled to consider dividend

  BSE ↗
• Filing

  Annual financial results for FY 2025-26 filed today

  BSE ↗

Fri, 22 May, 2026

• News

  Regulatory approval for a specific drug product in Saudi Arabia

  business-standard.com ↗
• Filing

  Company received Saudi FDA approval for Plerixafor, marking first global marketing authorization for specialty oncology…

  NSE ↗
• Filing

  Venus Remedies achieved first global regulatory approval (Saudi FDA) for specialty oncology drug Plerixafor, a signific…

  BSE ↗